Ventoux Biosciences, Inc
About Ventoux Biosciences, Inc
Ventoux Biosciences, Inc. is a pre-clinical stage biotechnology company developing first-in-class, disease-modifying therapies for immune-fibrotic conditions. The company, driven by a patient founder, focuses on underserved chronic conditions beginning with Dupuytren’s disease (palmar fibromatosis). Its lead small molecule asset, VEN-201, emerged from a data-driven discovery platform and is advancing as a potential non-surgical pharmacologic solution. The company is headquartered in Encinitas, California and was founded in 2022.
- 🔗 Client and Biotech Innovator Ventoux Biosciences Secures Critical Patent Protection - Procopio | Procopio
- 🔗 Ventoux Biosciences
- 🔗 Ventoux Biosciences
- 🔗 Ventoux Biosciences Launches Research Program Targeting Spinal Cord Injury with VEN-201
- 🔗 Ventoux Biosciences Secures U.S. Patent for Novel Therapy Targeting Dupuytren's Disease and Immune-Fibrotic Disorders
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Secured U.S. patent covering methods of treating immune-fibrotic disorders including Dupuytren’s disease.
- Launched research program exploring VEN-201 in translational preclinical models of spinal cord injury.
- Patient-founded company advancing VEN-201 as a potential non-surgical treatment for Dupuytren’s disease.
- Achieved breakthrough in pre-clinical trials for a new treatment of fibrosis while launching a new funding round.
Ask StreetZero about Ventoux Biosciences, Inc
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account